**Road Trip to TB Elimination: Packing the Essentials**

|  |  |  |
| --- | --- | --- |
| **Time** | **Session - Room** | **Speakers** |
| **7:00** | Registration, Exhibit/ Poster Set-Up, Breakfast Buffet with protein - FOYER |
| **8:00** | **Welcome and Opening Remarks - BALLROOM**April King-Todd, RN, BSN, MPH, CTCA President, Los Angeles County Department of Public Health (LACDPH) and Survivor Advocate Rosemarie (Reina) Whitney |
| **8:15** | **Jayne Ash Memorial Keynote Address: *Car Seats Are Essential:* Preventing and Identifying Pediatric TB in Contact Investigations - BALLROOM**At the end of this session, participants will be able to identify the following to improve patient outcomes:

|  |  |
| --- | --- |
| * Relevant information needed to guide TB treatment decisions for pediatric contacts
* When to use IGRAs for pediatric contacts
* LTBI treatment options for pediatric contacts
 | 96.85%123 |

 | **Faculty:**Kristen Wendorf, MD, MS, Program Development Section Chief, California Department of Public Health (CDPH) TB Control Program (TBCB) |
| **9:15** | **Planning Your Itinerary:Using California Epidemiology to Drive TB Control and Prevention** At the end of this session, participants will be able to:* Identify populations at risk for TB infection and disease in order to guide effective, culturally appropriate TB control efforts
 | **Coordinator:** Tessa Mochizuki, MPH, Prevention Epidemiologist, CDPH TBCB **Faculty:** Pennan Barry, MD, MPH, Surveillance and EpiSection Chief, CDPH TBCB |
| **10:00** |
| **10:20** | **Essential Guidelines – Update: US LTBI Guidelines, NTCA Statement: Targeted Testing and Treatment of LTBI in the US**At the end of this session, participants will be able to do the following to improve patient outcomes:* Describe the companion statement being developed by NSTC for the testing and treatment of LTBI.
 | **Coordinator and Faculty:** Charlie Crane, MD, TB Consultant**Additional Faculty:** Randall Reves, MD, M. Sc., Professor, University of Colorado |
| **11:00** | **Using GPS to Find Your Way: Whole Genome Sequencing**At the end of this session, participants will be able to do the following to improve patient outcomes:* Identify the fundamentals of WGS and how WGS differs from prior molecular analysis methods for TB for improved outbreak and cluster investigations
* Explain universal WGS in the U.S. and the national vision for using WGS to improve TB outbreak and cluster investigations Request WGS analysis when appropriate to improve TB outbreak and cluster investigations
* Describe the advantages and challenges in using WGS data in an outbreak or genotype cluster investigation to more precisely identify outbreaks and outbreak cases to interrupt transmission
 | **Coordinator**: Tambi Shaw, MPH, Outbreak Prevention and Control Section (OPCS) Chief, CDPH TBCB**Faculty:** Wendy Noboa, MS CDC Public Health Advisor, LACDPH; Sarah Talarico, PhD, MPH, CDC Division of TB Elimination (DTBE); Martin Cilnis, MS, MPH, Epi, OPCS, CDPH TBCB |

|  |  |  |
| --- | --- | --- |
| **12:00** | **Awards Buffet Luncheon (hosted) Awards: EC Outgoing, Andy Lopez, Brenda Ashkar, Private Provider, Renteln** | **Moderators and Faculty:** |
| **1:15** | **Breakout A. 3 Point Inspection Under the Hood: Case Radiograph Session**At the end of this session, participants will be able to do the following to improve patient outcomes:* Apply appropriate diagnostic and management reasoning based on the appearance of radiographic findings in cases suspicious for TB, to improve overall case management
* Recognize radiographic manifestations of TB to improve clinical skills in TB diagnosis
 | **Coordinators and Faculty:** Chris Keh, MD, Dir., and Rocio Agraz-Lara, MSN, PHN, Nurse Mngr, TB Prevention and Control Program, San Francisco DPH**Additional Faculty:** Thienkhai H. Vu, MD, PhD, Assistant Clinical Professor, Dept. of Radiology andBiomedical Imaging, UCSF |
| **1:15** | **Breakout B. Taking the road less travelled: Novel contact investigation (CI) strategies and partnerships**At the end of this session, participants will be able to describe the following to improve patient outcomes:

|  |  |
| --- | --- |
| * How to implement a novel referral strategy to improve contact investigations
* How to use social media to identify contacts and epi. links
* Community partners that can help with contact investigation in hard-to-reach populations
 | 97.47%77 |

 | **Faculty:** Leslie Henry, Program Development Section, CDPH TBCB Lucinda Gardner, Epi, TB Control Division, Sonoma County DPHKristiana Dhillon, Epi, OPCS, CDPH TBCB |
| **1:15** | **Breakout C. Learning to drive: Introduction to Effective Contact Investigation (CI) Strategies**Note: This session will provide an overview of basic CI strategies. It is intended for staff new to TB investigations. At the end of this session, participants will be able to demonstrate the following to improve patient outcomes:* Three essential components of a TB interview
* Words that elicit open dialogue between the health care worker and patient
* Effective communication techniques to elicit household and non-household contacts
 | **Faculty:** Anne Cass, MPH, Technical Assistance Unit Chief, Program Development Section, CDPH, TBCB; Stephanie Spencer, MA, Program Liaison, Program Development Section, CDPH, TBCB |
| **2:15** | **Break** |
| **2:30** | **Tips to Ensure we all Arrive Safely: TB Mortality Study: Reviewed, Implications, Applying Lessons Learned**At the end of this session, participants will be able to do the following to improve patient outcomes:* Assess the frequency of TB-related deaths
* Identify risk factors for TB-related death
 | **Coordinator and Faculty:** Susan Strong, NP, TB Controller and Program Manager, San Bernardino County Dept. of Public Health **Additional Faculty:** Lisa Pascopella, PhD, MPH, Sr. Epidemiologist, SES, CDPHTBCB; Janice Louie, MD, MPH, Medical Director, TB Prevention and Control Program, SFDPH |
| **3:30****5:00** | **Packing for the unexpected:** **Tuberculosis in recipients of organ transplantation**At the end of this session, participants will be able to do the following to improve patient outcomes:

|  |  |
| --- | --- |
| * Describe the epidemiologic and clinical features of TB disease in persons who have received organ transplantation in CA and use this information for clinical decision-making
* Understand current TB screening practices for organ transplant donors and recipients, including variability between transplant centers and use this information for clinical decision-making
* Become familiar with pathway for reporting transplant- associated TB and roles of involved agencies, including local and state health departments, organ procurement organization (OPO), UNOS Disease Transmission Advisory Committee (DTAC), and CDC Office of Blood, Organ and Other Tissue Safety (BOOTS) and use this information for clinical decision-making
 | 98.29%115 |
|  |  |

Adjourn | **Coordinator and Faculty:** Shereen Katrak, MD, MPH, Medical Officer, CDPH TBCB **Additional Faculty:**Peter Chin-Hong, MD, Professor, School of Medicine, UCSFJeanne Soukup, RN, BSN, Patient Services and Reporting Unit, TBCB, LACDPHJefferson Jones, MD, MPH, Medical Officer and Epidemiologist, CDC Blood, Organ and Other Tissue Safety |

**CONTINUING EDUCATION CREDITS**

The Curry International Tuberculosis Center (CITC) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This educational conference is approved for 7.0 continuing education hours. The CITC designates this educational activity for a maximum of 7.0 *AMA PRA Category 1 Credit(s) TM*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CITC is approved as a provider of continuing education by the California State Board of Registered Nurses, Provider Number CEP 12308. This educational conference is approved for 7.0 continuing education hours.

Certificates will be emailed approximately eight to twelve weeks after the course to all participants who requested CME or nursing credits on their applications and who successfully complete the course. Successful completion includes attending the entire course and completing an online evaluation form. We contact all CME recipients 4-months after the course to help us with our long-term evaluation activities.

Thank you to all of our faculty members and coordinators/ moderators above and Conference Planning Committee Members not also contributing as faculty, coordinators/moderators and not named above: John Jereb, MD, Acting Associate Director of Science, DTBE CDC; Kelly Musoke, MPH, Acting Deputy Director, CITC UCSF, Michael Joseph, Program Liaison, PDS, CDPH TBCB; Claire Torres, MPH, TBCB, LACDPH, CDPH TBCB; Claire Torres, MPH, TBCB, LACDPH.